Baron Health Care Fund Q2 2026 Portfolio Activity
During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43.
Market news
12 items · search:live+archive
News sentiment over time
Daily average lexicon sentiment across 198 scored headlines over the last 8 days. For market-wide mood (VIX, breadth, regime), see Markets. For the learned model that predicts forward return from a headline, see Headline Forecast Model.
Apogee Enterprises Announces Date for Fiscal 2027 Second Quarter Results
MINNEAPOLIS, September 15, 2026--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, today announced the company will report its fiscal 2027 second quarter results on Tuesday, October 6, 2026, before the market opens. The Company will also host a conference call at 8:00 a.m. CT that day.
Julie K. Streich Joins Apogee Enterprises’ Board of Directors
MINNEAPOLIS, September 14, 2026--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, announced today that its Board of Directors has elected Julie K. Streich as an independent director and appointed her to the Audit Committee of the Board, effective September 11, 2026.
3 Russell 2000 Stocks We’re Skeptical Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Core & Main (CNM) Q2 Earnings and Revenues Surpass Estimates
Core & Main (CNM) delivered earnings and revenue surprises of +1.08% and +0.17%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?
Apogee Enterprises: Another Deal Amid Margin And Earnings Pressures
Apogee Enterprisesâ Kalwall & GroGlass deals add sales/EBITDA but raise leverage amid margin pressure. Find out why APOG stock is a hold.
Apogee (APOG) Agreed to Acquire GroGlass for Up to €62.5M. Can a High-Margin Niche Deliver the Promised Synergies?
Apogee Enterprises, Inc. (NASDAQ:APOG) entered into a definitive agreement to acquire Latvia-based SIA GroGlass for up to €62.5 million, approximately $72.5 million at current exchange rates, on a cash-free, debt-free basis. The €10 million contingent portion is payable over three years if GroGlass achieves financial targets. The transaction is expected to close in the third […]
AbbVie Anticipates Apogee Acquisition To Negatively Impact Adj Diluted EPS By $0.14 This Year, $0.46 In 2027, Accretion Beginning In 2032
AbbVie (NYSE:ABBV) today announced that it expects its acquisition of Apogee to negatively impact adjusted diluted earnings per share (EPS) by $0.14 in 2026 (partial year) and approximately $0.46 in 2027, with accretion
Apogee Enterprises to Acquire GroGlass
MINNEAPOLIS, September 02, 2026--Apogee Enterprises, Inc. (Nasdaq: APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, announced today that it has entered into a definitive agreement to acquire SIA "GroGlass" ("Groglass") for up to €62.5 million (approximately $72.5 million at current exchange rates) on a cash-free, debt-free basis, subject to customary closing conditions. The purchase price in
Apogee Enterprises Inks Agreement To Acquire SIA For Up To $72.5M
Apogee Enterprises, Inc. (NASDAQ:APOG), a leading provider of architectural building products and services, as well as high-performance coated materials used in a variety of applications, announced today that it has
AbbVie Completes Acquisition of Apogee Therapeutics
AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Apogee Therapeutics, Inc. (NASDAQ: APGE). With completion of the acquisition, Apogee is now part of AbbVie. Under the terms of the agreement, Apogee shareholders received $135.11 per share in cash, for a total equity value of approximately $10.9 billion.
Diagnostics
sourcesearch:live+archive
count12
archive_hits3
hintWorker/cron → market_news table for the default view; search spans the permanent news_archive plus a live Finnhub top-up